Video Center

The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, provides his perspective on how to use both TAS-102 and regorafenib in a metastatic CRC patients

Published: 24 January 2017

Recent Videos

video

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, gives her perspective on the proper way ...

video

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

Dr. Shore, MD, Director, Carolina Urologic Research Center, gives his perspective on how the treatment of advanced prostate cancer has ...

video

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, talks about if immunotherapy will be added ...

video

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, on the most promising data showcased at ASCO GU.

video

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Related Videos

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

video-image

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

video-image

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

video-image

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

video-image

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

video-image

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

video-image

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

video-image

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

video-image

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

video-image

Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

video-image

Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017

video-image

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

video-image

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

video-image

Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session

video-image

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

video-image

Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017

video-image

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

video-image

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

video-image

Freddie C. Hamdy, MD, informs us on the ProtecT study top line results

video-image

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

video-image

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

video-image

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

video-image

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer

video-image

Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer

video-image

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

video-image

Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017

video-image

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

video-image

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

video-image

Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

video-image

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

video-image

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

video-image

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

video-image

David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors

video-image

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

video-image

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

video-image

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

video-image

Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

video-image

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

video-image

Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017

video-image

Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

video-image

Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology

video-image

Charles Saunders, MD, considers EHR providers in an era of value-based care

video-image

Charles Saunders, MD, on the operational changes necessary to succeed in a value-based environment

video-image

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017

video-image

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

video-image

Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma

video-image

Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications

video-image

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer

video-image

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

video-image

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

video-image

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

video-image

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

video-image

Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing

video-image

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

video-image

Jonathan Hirsch, on precision medicine software helping oncologists make therapeutic decisions

video-image

Jonathan Hirsch, discusses how precision medicine is being used to help improve cancer treatment

video-image

Jonathan Hirsch, President and Founder, Syapse, on the value of sharing patient-specific information

video-image

Mike Kolodziej, MD, explains how Flatiron analytics help practices succeed in value based care

video-image

Mike Kolodziej, MD, on how the clinical data set at Flatiron helps oncologists

video-image

Mike Kolodziej, MD, discusses how technology is helping reform the way practices operate

video-image

Mike Kolodziej, MD, talks about how CMMI is changing the health care system

video-image

Mike Kolodziej, MD, explains the impact of the ACA on the insurance industry

video-image

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

video-image

Marcus Neubauer, MD, explains how clinical pathways differ from clinical guidelines

video-image

Marcus Neubauer, MD, discusses if clinical pathways create value in cancer care

video-image

Marcus Neubauer, MD, explains how clinical pathways save money when treating cancer

video-image

Maddy Herzfeld, on how oncology practices consume patient-reported data to improve patient care

video-image

Maddy Herzfeld, on solutions available for practices to implement better patient engagement

video-image

Maddy Herzfeld, discusses the challenges practices are facing when implementing patient engagement

video-image

Bobby Green, MD, on leveraging genomic testing into actionable data

video-image

Bobby Green, MD, discusses collaboration efforts between Flatiron and Foundation Medicine

video-image

Bobby Green, MD, on using genomic data to prescreen eligibility for clinical trials

video-image

Jeffrey Scott, MD, explains his vision for how GPOs must evolve in the era of value-based care

video-image

Jeffrey Scott, MD, discusses best practices for a GPO to help with value-based savings

video-image

Jeffrey Scott, MD, on how important the drug channel is compared to reduction in hospitalizations

video-image

Jeffrey Scott, MD, shares the highest-impact areas of focus for value-based care savings

video-image

Steve D’Amato, R.Ph., on whether the ACA changed access to care at New England Cancer Specialists

video-image

Steve D’Amato, R.Ph., explains how his practice helps patients get access to cancer care

video-image

Steve D’Amato, R.Ph., on why this is a challenging time for oncology practices

video-image

Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM

video-image

Steve D’Amato, R.Ph., talks about data capture and data analytics at New England Cancer Specialists

video-image

Ed Bassin, Ph.D., on working with hospital-based cancer centers vs community practices

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data can be used in the OCM model

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data is being used

video-image

Ira Klein, MD, discusses how limited distribution impacts the delivery of oral cancer agents

video-image

Ira Klein, MD, explains how risk management changes the way we manage supply chain

video-image

Ed Bassin, Ph.D., explains the challenges for oncologists and practices with the OCM model

video-image

Ed Bassin, Ph.D., on what oncologists should be thinking about as they approach value based care

video-image

Ira Klein, MD, on what the shift toward oral oncolytics means for the supply chain

video-image

Dave Terry, Chief Executive Officer, explains why practices should participate in APMs

video-image

Dave Terry, Chief Executive Officer, shares his thoughts on Alternative Payment Models of the future

video-image

Dave Terry, Chief Executive Officer, on the keys to success when participating in APMs

video-image

Debra Patt, MD, on what tele-health brings to cancer care

video-image

Linda Bosserman, MD, on deciding whether to participate in MIPS or AAPM

video-image

Linda Bosserman, MD, explains “Pick Your Pace” as it relates to participation in MACRA

video-image

Debra Patt, MD, explains using predictive analytics to improve cancer care delivery

video-image

Debra Patt, MD, explains how decision support tools improve the quality and delivery of cancer care

video-image

James Hamrick, MD, explains how EMRs help connect patients and caregivers

video-image

Harlan Levine, MD, on how cancer care navigators impact quality of care at City of Hope

video-image

Harlan Levine, MD, on treating patients in this era of high cost cancer drugs

video-image

Lili Brillstein, M.P.H., explains the requirements that must be met in an episode assessment

video-image

Lili Brillstein, M.P.H., shares her thoughts on the keys to success to make episodes of care work

video-image

James Hamrick, MD, on using real world evidence to learn how to treat cancer patients

video-image

Harlan Levine, MD, on the philosophy for establishing quality metrics as they relate to an ACO

video-image

Harlan Levine, MD, tells us about the continuous cycle of learning and improving at City of Hope

video-image

Lili Brillstein, M.P.H., explains how an episode of care is different from a bundled payment

video-image

Lili Brillstein, M.P.H., explains the primary goal of an episode of care

video-image

Linda Bosserman, MD, discusses the highlights of the MACRA panel at CCBS 2017

video-image

Linda Bosserman, MD, explains what MACRA means for oncologists today

video-image

Debra Patt, MD, explains how data systems help with patient care delivery in community oncology

video-image

James Hamrick, MD, shares his thoughts on how we are evolving toward a learning health care system

video-image

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

video-image

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

video-image

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

video-image

John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers

video-image

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

video-image

Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy

video-image

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

video-image

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

video-image

John L. Marshall, MD, talks about the results of the RESORCE trial

video-image

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

video-image

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

video-image

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

video-image

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

video-image

Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice

video-image

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

video-image

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

video-image

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

video-image

Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102

video-image

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

video-image

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

video-image

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

video-image

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

video-image

Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial

video-image

Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment

video-image

Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice

video-image

Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC

video-image

Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer

video-image

Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer

video-image

Johanna Bendell, MD, discusses the RESORCE trial data

video-image

Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform

video-image

Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment

video-image

Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice

video-image

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment

video-image

Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients

video-image

Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research

video-image

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

video-image

Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date

video-image

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017

video-image

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

video-image

Edith P. Mitchell, MD, on how classifications of gastric cancer subtypes are impacting treatment

video-image

Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative

video-image

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

video-image

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

video-image

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

video-image

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

video-image

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

video-image

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

video-image

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

video-image

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

video-image

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

video-image

Alexander Perl, MD, discusses treatment options for AML patients

video-image

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

video-image

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

video-image

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

video-image

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

video-image

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

video-image

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

video-image

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

video-image

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

video-image

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

video-image

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

video-image

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

video-image

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

video-image

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

video-image

David Miklos, MD, on developing an orphan drug for a small population of patients

video-image

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

video-image

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

video-image

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

video-image

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

video-image

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

video-image

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

video-image

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

video-image

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

video-image

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

video-image

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

video-image

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

video-image

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

video-image

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

video-image

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

video-image

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

video-image

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

video-image

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

video-image

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

video-image

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

video-image

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

video-image

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

video-image

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

video-image

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

video-image

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

video-image

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

video-image

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

video-image

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

video-image

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

video-image

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

video-image

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

video-image

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

video-image

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

video-image

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

video-image

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

video-image

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

video-image

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

video-image

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

video-image

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

video-image

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

video-image

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

video-image

Edward Copelan, MD, discusses the Levine Cancer Institute Program

video-image

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

video-image

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

video-image

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

video-image

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

video-image

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Michael Kauffman, MD, on how Selinexor works

video-image

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

video-image

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

video-image

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

video-image

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

video-image

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

video-image

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

video-image

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

video-image

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

video-image

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today

video-image

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

video-image

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

video-image

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

video-image

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

video-image

Richard M. Goldberg, MD, FASCO on regimen preference in mCRC 1st line treatment

video-image

Skip Burris, MD, talks about how CAR-Ts work, and the trials taking place at SCRI

video-image

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments

video-image

Nevena Damianov, MD interprets how new advanced HCC agents will integrate into HCC treatment

video-image

Alan Venook, MD discusses development of immunotherapies for non MSI-High CRC patients

video-image

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

video-image

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

video-image

Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)

video-image

Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients

video-image

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

video-image

Alexander Lesokhin, MD discusses the development of immunotherapies for multiple myeloma patients

video-image

Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC

video-image

Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML

video-image

David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients

video-image

Alexander Perl, MD, on the role of immunotherapy in treating hematological malignancies

video-image

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

video-image

Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

video-image

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab

video-image

Nevena Damianov, MD illustrates the promising classes and products for advanced, unresectable HCC

video-image

Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies

video-image

Laura Chow, MD discusses incorporating checkpoint inhibitors into standard of care

video-image

Richard Goldberg, MD, discusses selecting the right therapeutic approach for CRC patients

video-image

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

video-image

Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC

video-image

Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting

video-image

Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405

video-image

Jennie R. Crews, MD, looks at long-term efficacy with immunotherapies

video-image

Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3

video-image

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

video-image

Value Tools at ASCO 2016: Building a Framework for Prime Time (Part 3)

video-image

Laura Chow, MD, provides the rationale for studying PD-L1 inhibitors in SCCHN

video-image

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

video-image

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

video-image

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

video-image

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

video-image

Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy

video-image

Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC

video-image

Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)

video-image

Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients

video-image

Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)

video-image

Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients

video-image

Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact

video-image

Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor

video-image

Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting

video-image

Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy

video-image

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

video-image

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

video-image

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

video-image

Mark Levis, MD, discusses significance of the Quantum-R study

video-image

Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML

video-image

Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML

video-image

Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835

video-image

Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients

video-image

Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation

video-image

Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies

video-image

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

video-image

Julie Gralow, MD, on the KRISTINE study

video-image

Julie Gralow, MD, discusses the Monarch 1 study

video-image

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

video-image

Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients

video-image

Julie Brahmer, MD, on the importance of overall cost of therapy

video-image

Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC

video-image

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

video-image

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

video-image

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

video-image

Eunice S. Wang, MD, discusses the Quantum First Study

video-image

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML

video-image

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

video-image

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

video-image

David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC

video-image

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

video-image

Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets

video-image

Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)

video-image

Anthony El-Khoueiry, MD, discusses management of Nexavar (Sorafenib) toxicities in HCC

video-image

Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years

video-image

Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity

video-image

Alexander Perl, MD, discusses the Quantum First Study and potential implications

video-image

Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences

video-image

Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target

video-image

David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients

video-image

Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

video-image

Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study

video-image

Mark Levis, MD, on why the FLT3 target is important in AML

video-image

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

video-image

Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results

video-image

David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients

video-image

Howard Hochster, MD explains outcomes from the phase 3 CALGB/SWOG 80405 study

video-image

Howard Hochster, MD on mCRC treatment changes due to primary site of tumor impact.

video-image

Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC

video-image

Howard Hochster, MD on performance status importance in selecting treatment algorithms

video-image

Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405

video-image

Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies

video-image

Nevena Damianov, MD on the reasoning for studying PD-L1 inhibition in advanced HCC

video-image

Nevena Damianov, MD relays which late stage clinical studies will impact in advanced HCC

video-image

Jennie R. Crews, MD relays the unique side effects being seen with long-term use of immunotherapies

video-image

Jennie R. Crews, MD, explains if there is a stopping point where immunotherapy shouldn’t be used

video-image

Jennie R. Crews, MD, discusses the broad applicability and limitations with immunotherapy

video-image

Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)

video-image

Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients

video-image

Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients

video-image

Jennie R. Crews, MD talks about the goals of the ICLIO as developed by ACCC

video-image

Tanios Bekaii-Saab, MD, on outcomes of CALGB/SWOG 80405 regarding primary site of tumor

video-image

Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment

video-image

Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients

video-image

Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC

video-image

Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes

video-image

Philip Philip, MD on what is impressing him at ASCO 2016 in CRC

video-image

Nevena Damianov, MD discusses the toxicity concerns and how to manage them for sorafenib in HCC

video-image

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

video-image

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

video-image

Laura Chow, MD tells us about products in development for SCCHN

video-image

Laura Chow, MD discusses cross trial comparisons with Keytruda and Opdivo in head and neck cancers

video-image

Laura Chow, MD discusses the role of PD-L1 testing in SCCHN

video-image

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

video-image

Jeffrey A. Meyerhardt, MD on PD-1 or PD-L1 treatment strategies for MSI-Stable mCRC patients

video-image

Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients

video-image

Bert O'Neil, MD discusses decision making based on toxicities factor for later lines of mCRC therapy

video-image

Barbara Burtness, MD talks about new patient treatment insights based on the Keynote-055 study

video-image

Barbara Burtness, MD explains if the Keynote-012 study confirms the benefit seen with Keytruda

video-image

David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients

video-image

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients

video-image

Laura Chow, MD interprets the overall survival benefit with Opdivo in the CheckMate-141 study

video-image

Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen

video-image

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

video-image

Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study

video-image

Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithm

video-image

Robert Filgin MD explains the importance of cabozantinib as a tool in the RCC armamentarium

video-image

Robert Filgin MD provides an update on nivolumab (Opdivo) in RCC

video-image

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

video-image

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

video-image

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

video-image

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment

video-image

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study

video-image

Jeffrey A. Meyerhardt, MD explains results from the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD explains how OS from primary site of tumor may impact treatment

video-image

Jeffrey A. Meyerhardt, MD on the reliability of MSI-High as a predictor of response in mCRC

video-image

Jeffrey A. Meyerhardt, MD explains integration of Stivarga and Lonserf in later lines of treatment

video-image

Jeffrey A. Meyerhardt, MD, explains matching mutations and markers to therapies in CRC patients

video-image

Robert A. Figlin, MD on clinical study that lead to approval of lenvatinib (Lenvima)

video-image

Barbara McAneny, MD, reviews the COME HOME project’s influence on the Oncology Care Model

video-image

Richard Goldberg, MD, talks patient response with the combination of MEK and PD-1 inhibitors

video-image

Richard M. Goldberg, MD, FASCO on the importance of the NETTER-1 study

video-image

Richard M. Goldberg, MD, discusses the gastric cancer treatment algorithm based on the CRITICS study

video-image

Richard M. Goldberg, MD, FASCO on adjuvant pancreatic cancer news

video-image

Richard M. Goldberg, MD, FASCO on KRAS wild type or mutant in right or left-sided mCRC patients

video-image

Richard M. Goldberg, MD, FASCO discusses outcomes of the phase 3 CALGB/SWOG 80405 study

video-image

Bert O'Neil, MD on integrating regorafenib and trifluridine into later lines of mCRC treatment

video-image

Bert O'Neil, MD and the combination of ipilimumab with nivolumab in mCRC patients

video-image

Bert O'Neil, MD on the importance of choosing mCRC treatment based on primary tumor site

video-image

Barbara Burtness, MD on evidence for incorporating checkpoint inhibitors into treatment

video-image

Alexander Lesokhin, MD on the use of daratumumab to treat multiple myeloma patients

video-image

Alexander Lesokhin, MD provides an update on the CASTOR trial presented at ASCO 2016

video-image

Alexander Lesokhin, MD talks about the pros/cons of an all-oral regimen in the treatment of MM

video-image

Alexander Lesokhin, MD on sequencing therapies in relapsed multiple myeloma patients

video-image

Alexander Lesokhin, MD explains therapy combinations for newly diagnosed multiple myeloma patients

video-image

Alexander Lesokhin, MD talks about newly diagnosed multiple myeloma patients

video-image

Alan Venook, MD, balancing economics with the efficacy outcomes seen in 80405

video-image

Alan Venook, MD relays the optimal dose for regorafenib (Stivarga) in the 2nd line treatment of mCRC

video-image

Alan Venook, MD on integrating regorafenib and trifluridine into the 2nd line treatment of mCRC

video-image

Alan Venook, MD on reliability of MSI-High predictor fpr response to nivolumab (Opdivo) in mCRC

video-image

Alan Venook, MD relates data presented in EPIC study relates to CALGB/SWOG 80405

video-image

Alan Venook, MD, explains the biological difference between left-sided and right-sided CRC tumors

video-image

Bert O’Neill, MD, on making immunotherapy more effective in mCRC

video-image

Barbara Burtness, MD on the Keynote-055 study in SCCHN patients

video-image

Jeff Patton, MD, explains what could happen if the CMS ASP Experiment proceeds as planned by CMS

video-image

Bhuvana Sagar, MD, tells us about the Cigna medical home for oncologists

video-image

Participation in the Oncology Care Model (OCM) as explained by Barry Russo

video-image

Skip Burris, MD, discusses how precision medicine is changing cancer treatment

video-image

John Fox, MD, predicts if the ASCO Value Framework or NCCN Evidence Blocks will impact drug spend

video-image

Deborah Patt, MD, tells us how chemotherapy costs figure into total care

video-image

Robert Baird tells us what MIPS are and how practices might use them

video-image

Patrick Cobb, MD, discusses treatment innovations and managing patient’s expectations

video-image

Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

video-image

David Eagle, MD, compares treatment costs in different settings

video-image

Mary Kruczynski tells us how the Cost Drivers in Cancer Care study was developed

video-image

Ricky Newton, CPA, updates us on COPA

video-image

Ricky Newton, CPA, details how COPA’s website helps practice managers, pharmacists, and patients

video-image

Ricky Newton, CPA, explains the purpose of COPA’s new In-House and Specialty Pharmacies brief

video-image

Ricky Newton, CPA, tells us what follow up to expect from COPA’s new brief

video-image

Robert Baird fills us in on the Value-Based Purchasing Modifier's impact on Dayton

video-image

Robert Baird details how practices can prepare for the Value-Based Purchasing Modifier and MIPS

video-image

Robert Baird explains how Dayton physicians and payers are collaborating on APMs

video-image

Robert Baird answers questions on Dayton’s participation in the Oncology Care Model

video-image

Skip Burris, MD, outlines the scope of cancer clinical trials at SCRI

video-image

Skip Burris, MD, looks at the promise of immunotherapies in combination

video-image

Skip Burris, MD, explains goals and outcomes of the My Pathway trial

video-image

Skip Burris, MD, reflects on the promise and concerns with liquid biopsies

video-image

Ted Okon tells us why the CNS ASP Experiment is a bad idea

video-image

Embrace alternative payment models explains Ted Okon

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, explains the role an in-house pharmacy plays in the quality equation

video-image

Sue Naeyaert predicts whether we will see more cancer biosimilars soon

video-image

Sue Naeyaert tells us what to expect in pricing biosimilars

video-image

A look at the expansion of a biosimilar’s FDA label with Sue Naeyaert

video-image

Sue Naeyaert explains the proposed reimbursement of biosimilars by CMS

video-image

Sue Naeyaert provides her vision of the biosimilar products in development

video-image

Todd Murphree briefs us on ACHC’s oncology accreditation process

video-image

Todd Murphree, PharmD, discusses how ACHC accreditation benefits his practice

video-image

Ted Okon discusses the sessions that stand out at this year's annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon provides an overview of the Cost Drivers in Cancer Care study

video-image

Mary Kruczynski speaks to those who were unable to attend the 2016 Annual COA meeting

video-image

Mary Kruczynski tells us how the 2016 Annual COA meeting benefits health care providers

video-image

Mary Kruczynski reflects on highlights from COA

video-image

Lucio Gordan, MD, lists takeaways from COA that can benefit his own practice

video-image

Lucio Gordan, MD, debriefs providers who didn’t attend on highlights from COA

video-image

Lucio Gordan, MD, reflects on key messages from this year’s COA

video-image

Jeff Vacirca, MD, explains the relevance of the COA/Milliman study to his practice

video-image

Jeff Vacirca, MD, talks about what his community oncology practice is doing to survive

video-image

Jeff Patton, MD, explains how his practice is working to develop alternative payment models

video-image

COA is helping community oncologists by fighting the CMS ASP Experiment by Jeff Patton, MD

video-image

Jeff Patton, MD, explains how Tennessee Oncology benefits from being a member of COA

video-image

Jeff Patton, MD, explains why the 2016 COA meeting is a must attend meeting

video-image

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

video-image

Deborah Patt, MD, shares her concerns about the CMS ASP Experiment and Part B reimbursement

video-image

Deborah Patt, MD, points out how oncologists can reduce cancer costs

video-image

Deborah Patt, MD, details surprising outcomes from a recent cost study

video-image

Deborah Patt, MD, looks at the bigger expense drivers in cancer care

video-image

David Eagle, MD, gives his opinion on the CMS ASP Experiment

video-image

David Eagle, MD, enumerates what oncologists can do to bring cancer costs down

video-image

David Eagle, MD, lists outcomes from the COA study surprising to oncologists

video-image

David Eagle, MD, details the bigger expenses driving up cancer care costs based on the COA study

video-image

David Eagle, MD, compares costs for treating cancer vs. non-cancer based on the COA study

video-image

David Eagle, MD, talks about COA’s Cost Drivers of Cancer Care study

video-image

Bhuvana Sagar, MD, discusses Cigna’s work with oncologists to find alternative payment models

video-image

Bhuvana Sagar, MD, explains the need for alternative payment models in oncology

video-image

Barry Russo explains the impact of the CMS ASP Experiment

video-image

Practices need to get ready to replace buy and bill explains Barry Russo

video-image

Bruce Gould, MD, explains the characteristics that makes a practice ready for OCM

video-image

Brad Prechtl briefs us on his concerns with the“Medicare Experiment” and its impact

video-image

Brad Prechtl tells how his practice is working to improve cancer care

video-image

Brad Prechtl talks about how community oncology practices can survive today

video-image

Brad Prechtl explains the benefits of community oncology practices joining forces

video-image

Bhuvana Sagar, MD, forecasts the possible Cigna adoption of a Medicare OCM model

video-image

Barry Russo explains how important it is to embrace alternative payment models

video-image

Barry Russo tells us how his practice is getting ready for value-based care

video-image

Patrick Cobb, MD, FACP, looks ahead to treatment innovations that will make a difference

video-image

Patrick Cobb, MD, FACP, talks about some exciting, recent innovations in cancer treatment

video-image

Michael Diaz, MD, talks about working with payers to add quality and value

video-image

Michael Diaz, MD, discusses the challenges in adopting quality and value measures

video-image

Michael Diaz, MD, talks about why the community oncology setting is the best value for patients

video-image

John Fox, MD, talks about how Priority might use the ASCO and NCCN value tools

video-image

John Fox, MD, talks about the new value tools from ASCO and NCCN

video-image

John Fox, MD, provides perspective on collaborating with providers on clinical pathways

video-image

A look at cancer clinical pathways with Charles Bane, MD

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, discusses the practicality of the value tool at Dayton Physicians Network

video-image

Perspective on the NCCN Evidence Blocks by Charles Bane, MD

video-image

Perspective on the ASCO Value Framework by Charles Bane, MD

video-image

Bruce Gould, MD, explains how the value tools could be used in the community practice setting

video-image

Perspective on the NCCN Evidence Blocks provided by Bruce Gould, MD

video-image

Perspective on the ASCO Value Framework provided by Bruce Gould, MD

video-image

Bruce Gould, MD, explains ASCO’s policy toward clinical pathways at this time

video-image

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

video-image

Bruce Gould, MD, describes the concerns his practice has with clinical pathways

video-image

Barbara McAneny, MD, explains why CMS implemented the ASP experiment

video-image

Barbara McAneny, MD, informs as to what practices should know about MACRA

video-image

Barbara McAneny, MD, discusses COME HOME’s adaptability to other community oncology practices

video-image

Barbara McAneny, MD, talks about the COME HOME project’s impact on community oncology practices

video-image

Barbara McAneny, MD, discusses the COME HOME project’s future

video-image

Patrick Soon-Shiong, MD, FRCS(C), FACS, discusses the Cancer Moonshot

video-image

Patrick Soon-Shiong, MD, tells us why it is important to target the tumor microenvironment

video-image

Patrick Soon-Shiong, MD, FRCS(C), FACS, describe the GPS Cancer test

video-image

Patrick Soon-Shiong, MD, FRCS(C), FACS, explains why have we not won the war on cancer

video-image

John Sprandio, MD explains why practices need analytics in an alternative payment model

video-image

John Sprandio, MD discusses why his practice partnered with Vantage Cancer Care Network

video-image

John Sprandio, MD explains why oncologists should practice in an IPA model

video-image

John Sprandio, MD, tells us about the economic reality of an oncology medical home

video-image

John Sprandio, MD, discusses how patient-centered oncology medical homes impacted on ER visits

video-image

John Sprandio, MD, discusses the degree services drive the likelihood of achieving clinical outcomes

video-image

John Sprandio, MD, explains how his practice worked with Capital Blue Cross

video-image

John Sprandio, MD, explains how his practice worked with CMS to help develop the Oncology Care Model

video-image

John Sprandio, MD, discusses the changes his practice made to become a patient centered medical home

video-image

Jennifer Carter, MD, explains how N-of-One uses precision medicine to recommend treatment strategies

video-image

Jennifer Carter, MD, MPH, explains how oncology clinical trial design is adopting precision medicine

video-image

Jennifer Carter, MD, MPH, tells us the biggest challenges facing adoption of precision medicine

video-image

Jennifer Carter, MD, MPH, explains how hospital systems can launch a precision medicine program

video-image

Jennifer Carter, MD, MPH, describes how precision medicine can change the way cancer is treated

video-image

Ira Klein, MD, MBA, FACP, discusses the challenges as we move to a more risk bearing environment

video-image

Ira Klein, MD, MBA, FACP, explains how oncologists can support their primary care colleagues

video-image

Ira Klein, MD, MBA, FACP, discusses if oncology has a meaningful role to play in population health

video-image

Harold Miller explains what types of payment models hold the most promise for oncologists

video-image

Harold Miller discusses PCOP and how it would decrease spending on cancer care

video-image

Harold Miller discusses the opportunities to reduce spending on cancer care without harming patients

video-image

Harold Miller discusses the barriers in the fee for service model

video-image

Gary Palmer, MD, JD, MBA, discusses how NantWorks and NantHealth is involved in the Cancer Moonshot

video-image

Gary Palmer, MD, JD, MBA, tells us when the GPS Cancer test will be available

video-image

Gary Palmer, MD, JD, MBA, describes the clinical utility of the GPS Cancer test

video-image

Gary Palmer, MD, JD, MBA, tells us about the mission of NantWorks and NantHealth

video-image

Gary Palmer, MD, JD, MBA, discusses how precision medicine figures into cancer treatment algorithms

video-image

John Iacuone, MD, MBA, explains what capital improvements and services VCCN provides to oncologists

video-image

John Iacuone, MD, MBA, explains how practices stay independent in pay for performance environment

video-image

John Iacuone, MD, MBA, discusses the economic advantage for oncologists that join the VCCN

video-image

John Iacuone, MD, MBA, explains why Vantage Cancer Care Network was created and their mission

video-image

Kavita Patel, MD, MS discusses how important cancer care management is to Medicare

video-image

Kavita Patel, MD, MS, explains how 340B is impacting cancer care

video-image

Kavite patel, MD, MS, tells us whether ACOs are having an impact on oncologists

video-image

Kavita Patel, MD, MS, describes the Triple Aim

video-image

Linda Bosserman, MD, discusses the challenges with the rise in consumerism and patient integration

video-image

Linda Bosserman, MD, explains how her practice implemented structural data collection in an EMR

video-image

Linda Bosserman, MD, explains how her private practice served two Safety Net hospitals in her region

video-image

Madelyn Trupkin Herzfeld discuses how cancer patients are involved in treatment decision-making

video-image

Madelyn Trupkin Herzfeld defines patient engagement, and the tools patients use with their care team

video-image

Madelyn Trupkin Herzfeld explains what does Carevive does to help patients with cancer

video-image

Michael Kolodziej, MD, discusses alternative payment models of the future

video-image

Michael Kolodziej, MD, describes the breadth and depth of alternative payment models

video-image

Michael Kolodziej, MD, tells us why alternative payment models are needed

video-image

William Harwin, MD, tells us what smaller practices can learn from his experience

video-image

William Harwin, MD, explains how quality measures are being integrated into his practice

video-image

William Harwin, MD, tells us about the ancillary services his pracdtice has to help patients

video-image

William Harwin, MD, gives his opinion if practices can survive in today's value based environment

video-image

David Lansky gives the employer perspective on quality cancer care

video-image

David Lansky has ideas on how patient reported data can be captured

video-image

David Lansky describes how patient reported outcomes can measure of health care system improvement

video-image

David Lansky explains how can we improve efficiency in the health care system

video-image

Bobby Green, MD, MSCE, discusses Flatiron’s approach to tackling today's value issues

video-image

Bobby Green, MD, MSCE, discusses how we use these data to drive quality

video-image

Bobby Green, MD, MSCE, tells us which data is needed to curate a complete picture of the patient

video-image

Bobby Green, MD, MSCE, explains the frustrations with data coming from oncology practices

video-image

Debra Patt, MD, discusses what the future holds for quality improvement in oncology

video-image

Debra Patt, MD, explains what some of the limitations of quality improvement measurements are

video-image

Debra Patt, MD, tells us the history of quality improvement

video-image

Charles Rosen, MD, discusses avoidable costs in cancer care

video-image

Charles Rosen, MD, explains how team care is important to improving cancer care

video-image

Charles Rosen, MD, discusses the future of specialty care nationally

video-image

Andrew Schorr explains how his story represents a change in the patient and doctor relationship

video-image

Andrew Schorr tells us the information and resources that patients want out of cancer websites

video-image

Andrew Schorr tells us his story as a 2-time cancer survivor

video-image

STEAM trial may not change treatment paradigm for metastatic CRC ASCO 2016

video-image

Regorafenib experience and integrating TAS-102 for advanced CRC ASCO GI 2016

video-image

Planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers ASCO Gi 2016

video-image

How has the last 10 years changed the way you treat metastatic colorectal cancer ASCO GI 2016

video-image

Potential cases to use Regorafenib over TAS-102 ASCO GI 2016

video-image

More money should be allocated to early detection and screening in colorectal cancer ASCO GI 2016

video-image

Biggest questions facing the treatment of colorectal cancer ASCO GI 2016

video-image

PD-L1 markers in MMR deficient cancers ASCO GI 2016

video-image

Mismatch Repair (MMR) deficient and the use of PD-1 blockade ASCO GI 2016

video-image

ERCC1 not a valid prognostic or predictive factor in advanced CRC ASCO GI 2016

video-image

RAS mutation in patients with metastatic colorectal cancer ASCO GI 2016

video-image

Design of the RECOURSE trial on which the FDA approved TAS-102

video-image

RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC

video-image

Importance of performance status prior to starting regorafenib at ASCO GI 2016

video-image

Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

video-image

Choosing which EGFR inhibitor to use in second line treatment of mCRC patients At ASCO GI 2016

video-image

TAS-102 versus 5-flourouracil and other more familiar agents ASCO GI 2016

video-image

RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016

video-image

RECOURSE trial did performance status impact benefit from TAS-102 at ASCO GI 2016

video-image

Integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016

video-image

ASCO GI 2016 Optimal Dosage Using Regorafenib Colorectal Cancer

video-image

Managing patients on regorafenib including adverse events

video-image

Next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies

video-image

KEYNOTE-028 results with pembrolizumab

video-image

Pembrolizumab looks promising according to KEYNOTE-028 results

video-image

Immunotherapy Shows Promise in MSI-High Colorectal Cancer

video-image

Pancreatic Cancer News from ASCO GI 2016

video-image

Weekly T-DM1 surprising or disappointing ASCO GI 2016

video-image

GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016

video-image

Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas ASCO GI 2016

video-image

Post-operative adjuvant therapy for resectable patients with node positive oesophageal cancer ASCO GI 2016

video-image

FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016

video-image

Future of TAS-102 and regorafenib for patients with colorectal cancer

video-image

TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1

video-image

RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib

video-image

Does the Asian population differ from the western populations in regards to gastric cancers

video-image

The future of gastric cancers will be targeted agents including immunotherapy

video-image

FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma

video-image

Phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma

video-image

Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer ASCO GU 2016

video-image

Using new therapies earlier in prostate cancer may returns better results

video-image

Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium

video-image

Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer

video-image

Choosing predictive markers for PD-1 and PD-L1 inhibitors in RCC - Dr. Walter Stadler

video-image

Avelumab tolerable for patients according to JAVELIN Solid Tumor phase Ib trial

video-image

Evaluation of response to enzalutamide consecutively after disease progression on abiraterone prednisone

video-image

Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015

video-image

ASH 2015 Data Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab

video-image

Precision Medicine Coming to Bone Marrow Transplant

video-image

Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016

video-image

Advances In B-Cell Lymphoma From ASH 2015

video-image

Real World Experience Idelalisib - Rituximab Combination for Relapsed CLL

video-image

Jeffrey A. Meyerhardt, MD, discusses how consensus molecular subtypes help with CRC treatment

video-image

Ed Bassin, Ph.D., on if there will be health care savings with the implementation of the OCM